Immunogenicity and antitumor efficacy of the recombinant adenovirus expressing E7 and E6 fussion proteins of HPV type 16 in mice
10.3760/cma.j.issn.0254-5101.2012.03.021
- VernacularTitle:HPV16E7E6重组腺病毒的构建及免疫效果评价
- Author:
Jiao REN
;
Li ZHAO
;
Houwen TIAN
;
Jian GAO
;
Jing FENG
;
Zheng PANG
;
Xiaobing WU
;
Wenjie TAN
;
Li RUAN
- Publication Type:Journal Article
- Keywords:
Human papillomavirus type 16;
Cervical cancer;
Immunotherapy;
Adenovirus vector
- From:
Chinese Journal of Microbiology and Immunology
2012;32(3):276-280
- CountryChina
- Language:Chinese
-
Abstract:
ObjectiveTo construct one recombinant adenovirus AdE7E6 expressing HPV16 E6 and E7 fusion protein as candidate for HPV16 therapeutic vaccine.MethodsThe codon-optimized E6 and E7 gene,were fused to create one open reading frame,then inserted into adenovirus vector pCD316.A strain of recombinant adenovirus was constructed through homologous recombinant in 293 cells,and identified by PCR and Western blot.Finally,it was employed to study it's immunogenicity and the activity of the tumor growth regression.ResultsThe PCR result showed that E6E7 fusion gene had been integrated in recombinant Ad5 DNA.Western blot test confirmed that the E6E7 fusion protein was highly expressed in 293 cells infected with Ad5E7E6 recombinant adenovirus.The recombinant adenovirus elicited significant E7 specific CD8+ T lymphocyte response in vaccinated mice.These responses could completely prevent the TG-1 tumor cell bearing mice treated with AdE7E6 from developing into tumor.ConclusionThese results suggested that rAd5E7E6 could be a potent vaccine candidate for the treatment of HPV16-associated tumors and their precancerous transformations.
